Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.
about
Androgen replacement therapy in the aging maleCancer treatment-related bone disease.Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects.Diethylstilboestrol for the treatment of prostate cancer: past, present and future.Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy.Androgen deprivation therapy for prostate cancer: new concepts and concerns.Treatment-related osteoporosis in men with prostate cancer.Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.Estrogenic side effects of androgen deprivation therapy.Men, bone and estrogen: unresolved issues.Therapeutic benefit of bisphosphonates in the management of prostate cancer-related bone disease.Regulation of body composition by androgens.n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention.Sarcopenia during androgen-deprivation therapy for prostate cancer.Therapy Insight: osteoporosis during hormone therapy for prostate cancer.Biphosphonates in advanced prostate and renal cell cancer--current status and potential applications.Osteoporosis management in prostate cancer patients treated with androgen deprivation therapyContemporary use of hormonal therapy in prostate cancer: managing complications and addressing quality-of-life issues.Bone health and the female athlete triad in adolescent athletes.A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapyComparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study.Changes in bone health and skeletal-related events following implementation of a multidisciplinary consensus statement guiding surveillance and treatment of men undergoing androgen deprivation therapy for prostate cancer.Emerging drugs for the management of cancer treatment induced bone loss.Improving the management of patients with prostate cancer receiving long-term androgen deprivation therapy.Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled sChanges in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.Sex differences in the estrogen-dependent regulation of temporomandibular joint remodeling in altered loading.Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study.Fracture risk in Danish men with prostate cancer: a nationwide register study.Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.Mandibular and femoral growth alteration after sex hormone disruption in growing mice.Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma.The relationship between daily calcium intake and bone mineral density in men with prostate cancer.The effects of oestrogen exposure on bone mass in male to female transsexuals.
P2860
Q24551170-00920568-C315-48A6-B825-B7A2B3F0CB1FQ30438185-2A493BCD-0B54-4B0D-89B3-90DB8C51811AQ33610869-325FC263-49E1-4BB0-9606-B0F167125F5FQ34386403-C0D976F9-6E40-4820-9254-F71A377ECC9BQ34497901-F095968C-1722-41D6-9E5E-CCB2539EE4A1Q34617845-052DEF70-E13D-4370-81D0-94AA8C0AC2C8Q34617878-D413ECF9-E743-4185-A3F0-17F29A9A7CD6Q34617892-D4481232-21E0-4E78-A39A-8A7AA28F527BQ34743239-6D81F0E7-BA10-42D3-9E98-A035F859D448Q35121399-188CD8B4-6523-4431-931E-B40C5595E46EQ35124704-AF27EA5D-084F-4C71-B662-B27FE821AF3CQ35667540-4B497EFA-C1C4-4F89-A115-F8BF584A34C1Q36131716-9CC2317E-C8BD-43E3-8C17-07540CEE1BF2Q36212442-4BAA8A90-40F5-4F5D-BADE-3BCF5ED77EF2Q36395060-EB599653-1449-4FB9-AFD8-0AB1B0274CD7Q36403183-A4D70F37-F6EC-40EA-B47D-B05BB442D35DQ36416751-EA31265D-4103-496F-9986-3D55DAFD742EQ36710276-A2A54B53-F861-4AAC-A62A-A3E0C1A3EB47Q36892518-8E18C372-40DF-49D1-B22B-8117380CDF41Q37333126-C099DA98-AE6B-417C-9699-EFA4D3B7ED41Q37681882-8A1495FC-2A57-41BC-A6A5-F818CEBD980BQ37693156-3B89BE2F-3D38-4A7B-9569-2FBD7DAEE8B9Q37727235-E6D2E01B-A12C-4A6A-B628-26FC804D2029Q38016531-B3149EA3-5810-428B-A52D-97E1F5E228DEQ42618799-E1C38778-AAD6-40E4-AFF3-663803B7804DQ46705671-A2076559-4863-4D09-B6A3-B1CFECB53B55Q47930252-CE2ADBEE-E49C-4E05-BB86-D8123245B1B3Q49037718-04117DAE-F465-443A-AE55-92E485B1D038Q50545998-89580F8F-7B95-4819-8BD1-6E7F6FFE88E6Q50953817-13A38A4F-9CA8-45DA-9726-8DD288A2A3FFQ51482681-09F3B116-1427-40E8-969C-5BF7AD7DF9D5Q52548115-AC68E8D1-583F-4686-B6BB-FDDBB9F892D6Q53239932-0163F618-403F-4536-8513-6ABF1F2F19C0Q54099092-5D537A02-AE55-4F74-BB7E-80648742FEAE
P2860
Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Bone mineral density in patien ...... chidectomy and with estrogens.
@ast
Bone mineral density in patien ...... chidectomy and with estrogens.
@en
type
label
Bone mineral density in patien ...... chidectomy and with estrogens.
@ast
Bone mineral density in patien ...... chidectomy and with estrogens.
@en
prefLabel
Bone mineral density in patien ...... chidectomy and with estrogens.
@ast
Bone mineral density in patien ...... chidectomy and with estrogens.
@en
P2093
P356
P1476
Bone mineral density in patien ...... chidectomy and with estrogens.
@en
P2093
P2888
P356
10.1007/BF00298427
P407
P577
1995-08-01T00:00:00Z